Back

Mavacamten real-world experience: insights from the Dutch HCM Network.

1 September 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Myocardial disease and valvular heart disease: miscellany Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Peter-Paul Zwetsloot

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Radiofrequency septal ablation as a therapeutic option in refractory obstructive hypertrophic cardiomyopathy to myectomy: a case series
Doctor F. De Brito Fortuna (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Impact of sodium-glucose co-transporter inhibitors in mortality and decongestion in cardiac amyloidosis: A systematic review and meta-analysis
Mrs C. Espirito Santo (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Temporal and demographic disparities in cardiogenic shock mortality among patients with ischemic cardiomyopathy in the United States, 1999-2020
Doctor A. Zafar (Wigan, GB)
Abstract Slides Video
Presentation thumbnail
Cardiac mechanics in primary mitral regurgitation: effect of exercise in cardiac strain and hemodynamic parameters
Doctor I. Dimitroglou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The prognostic value of small psoas muscle area in patients undergoing mitral edge-to-edge repair
Doctor R. Shigeno (Okayama, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease and valvular heart disease: miscellany

The Event

Event poster

ESC Congress 2025

1 September 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy
thumbnail
Congress Presentation
Real-world symptom and echocardiographic improvement in obstructive HCM patients treated with mavacamten: evidence of favorable disease modification
thumbnail
Congress Presentation
Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) - Early findings from COMPASS-HCM

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources